November 3, 2025 — Leads & Copy — Hims & Hers Health, Inc. (NYSE: HIMS) reported strong financial results for the third quarter ended September 30, 2025, with revenue up 49% and Adjusted EBITDA up 53% year-over-year.
The company is in active discussions with Novo Nordisk to make Wegovy injections and oral Wegovy available through its platform.
Third Quarter 2025 Financial Highlights:
Revenue: $599.0 million, a 49% increase year-over-year.
Gross Margin: 74%.
Net Income: $15.8 million.
Adjusted EBITDA: $78.4 million, a 53% increase year-over-year.
Net Cash Provided by Operating Activities: $148.7 million.
Free Cash Flow: $79.4 million.
Financial Outlook:
Fourth Quarter 2025:
Revenue: $605 million to $625 million.
Adjusted EBITDA: $55 million to $65 million.
Full Year 2025:
Revenue: $2.335 billion to $2.355 billion.
Adjusted EBITDA: $307 million to $317 million.
Hims & Hers will host a conference call on November 3, 2025, at 5:00 p.m. ET to review the results. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at investors.hims.com.
Contact:
investors.hims.com
Source: Hims & Hers Health, Inc.
Source: Hims & Hers Health, Inc.
